Clincierge Releases Study on Patient Experience in Clinical Trials
Clincierge has released "Voice of the Patient," a research report examining the patient experience in clinical trials of rare diseases.
Findings in "Voice of the Patient" include:
- Sixty-two percent of patients and 59% of caregivers say travel stopped them from participating in a clinical trial, while 42% of patients and 47% of caregivers say financial issues stopped them from participating.
- Of patients who participated in a clinical trial, 68% say travel in previous clinical trials has been "difficult" and 95% say they "seriously" considered dropping out because of challenges associated with travel.
- Sixty-five percent of patients say receiving reimbursements made it "a lot" easier to remain in a clinical trial. However, one in three say it has taken a month or more to receive reimbursement while participating in a trial.
Read more about the report here.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
